GFAP and Alzheimer disease: Several BBMs including phosphorylated tau (p‐tau), amyloid beta (Aβ)42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) detect AD pathological changes or their downstream effects.